Glycoprotein (
GP) IIb/IIIa inhibitors are beneficial in
unstable angina/non-
ST-segment elevation myocardial infarction (UA/
NSTEMI). In large trials, the
GP IIb/IIIa inhibitors
tirofiban and
eptifibatide were each found to reduce the risk of death or
myocardial infarction (MI) in these patients at 30 days. These agents appear to be of greatest benefit in patients with a positive
troponin at baseline, diabetes or ST-segment depression, recurrent angina, prior
aspirin use, or a Thrombolysis In
Myocardial Infarction (TIMI) risk score > or = 4. The Treat angina with
Aggrastat and determine Cost of
Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI-18 trial was designed to compare the benefits of an early invasive versus a conservative strategy in high-risk UA/
NSTEMI patients treated with
GP IIb/IIIa inhibition. Patients were treated with
tirofiban (for 48 h) plus
aspirin and
heparin and randomized to either invasive
therapy (coronary angiography and revascularization when feasible) or
conservative treatment (angiography only for patients with recurrent
ischemia at rest or a positive stress test). A significant reduction in death or MI was demonstrated at 30 days (p = 0.02) and at 6 months (p = 0.0498). Death, MI, or
rehospitalization for an
acute coronary syndrome was also reduced with the invasive
therapy at six months (p = 0.025). These results provide evidence to physicians that early
GP IIb/IIIa inhibition in combination with a prompt invasive approach should be used more widely in UA/
NSTEMI patients, particularly those at high risk.